Brent Eilefson - Celcuity LLC General Counsel
| CELC Stock | USD 12.80 0.05 0.39% |
Executive
Brent Eilefson is General Counsel of Celcuity LLC
| Address | 16305?36th Avenue North, Minneapolis, MN, United States, 55446 |
| Phone | 763 392 0767 |
| Web | https://www.celcuity.com |
Celcuity LLC Management Efficiency
The company has return on total asset (ROA) of (0.2393) % which means that it has lost $0.2393 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5759) %, meaning that it created substantial loss on money invested by shareholders. Celcuity LLC's management efficiency ratios could be used to measure how well Celcuity LLC manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.35. In addition to that, Return On Capital Employed is expected to decline to -0.39. At present, Celcuity LLC's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.35).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MSc MD | AnaptysBio | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Priya Raina | AnaptysBio | N/A | |
| Ami Knoefler | Adagene | N/A | |
| Marianna Zipeto | Champions Oncology | N/A | |
| Paige Mahaney | C4 Therapeutics | N/A | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| William Winston | Werewolf Therapeutics | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Roy Pollock | C4 Therapeutics | N/A | |
| Daron Evans | Rezolute | 50 | |
| David MS | Ikena Oncology | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.24 |
Celcuity LLC Leadership Team
Elected by the shareholders, the Celcuity LLC's board of directors comprises two types of representatives: Celcuity LLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celcuity. The board's role is to monitor Celcuity LLC's management team and ensure that shareholders' interests are well served. Celcuity LLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celcuity LLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dabt Ph, VP RD | ||
| Eric Lindquist, Chief Officer | ||
| Sheri Smith, Acting Operations | ||
| MBA III, Chief Officer | ||
| Brian Sullivan, Chairman CoFounder | ||
| Lance Laing, Chief CoFounder | ||
| Igor MD, Chief Officer | ||
| Vicky Hahne, Chief Officer | ||
| MBA MD, Senior Development | ||
| Brent Eilefson, General Counsel |
Celcuity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celcuity LLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 310.25 M | ||||
| Shares Outstanding | 37.13 M | ||||
| Shares Owned By Insiders | 13.05 % | ||||
| Shares Owned By Institutions | 81.47 % | ||||
| Number Of Shares Shorted | 3.09 M | ||||
| Price To Earning | (23.45) X | ||||
| Price To Book | 3.19 X | ||||
| EBITDA | (58.31 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Celcuity LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Celcuity LLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Celcuity Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Celcuity Llc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celcuity LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Celcuity Stock refer to our How to Trade Celcuity Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celcuity LLC. If investors know Celcuity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celcuity LLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Return On Assets (0.24) | Return On Equity (0.58) |
The market value of Celcuity LLC is measured differently than its book value, which is the value of Celcuity that is recorded on the company's balance sheet. Investors also form their own opinion of Celcuity LLC's value that differs from its market value or its book value, called intrinsic value, which is Celcuity LLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celcuity LLC's market value can be influenced by many factors that don't directly affect Celcuity LLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celcuity LLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Celcuity LLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celcuity LLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.